Literature DB >> 15950321

Oxidative modification and down-regulation of Pin1 in Alzheimer's disease hippocampus: A redox proteomics analysis.

Rukhsana Sultana1, Debra Boyd-Kimball, H Fai Poon, Jain Cai, William M Pierce, Jon B Klein, William R Markesbery, Xiao Zhen Zhou, Kun Ping Lu, D Allan Butterfield.   

Abstract

Alzheimer disease (AD) is characterized neuropathologically by intracellular neurofibrillary tangles (NFT) and of extracellular senile plaques (SP), the central core of which is amyloid beta-peptide (Abeta) derived from amyloid precursor protein (APP), a transmembrane protein. AD brain has been reported to be under oxidative stress that may play an important role in the pathogenesis and progression of AD. The present proteomics study is focused on identification of a specific target of protein oxidation in AD hippocampus that has relevance to the role of oxidative stress in AD. Here, we report that the protein, Pin1, is significantly down-regulated and oxidized in AD hippocampus. The identity of Pin1 was confirmed immunochemically. Analysis of Pin1 activity in AD brain and separately as oxidized pure Pin1 demonstrated that oxidation of Pin1 led to loss of activity. Pin1 has been implicated in multiple aspects of cell cycle regulation and dephosphorylation of tau protein as well as in AD. The in vivo oxidative modification of Pin1 as found by proteomics in AD hippocampus in the present study suggests that oxidative modification may be related to the known loss of Pin1 isomerase activity that could be crucial in AD neurofibrillary pathology. Taken together, these results provide evidence supporting a direct link between oxidative damage to neuronal Pin1 and the pathobiology of AD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15950321     DOI: 10.1016/j.neurobiolaging.2005.05.005

Source DB:  PubMed          Journal:  Neurobiol Aging        ISSN: 0197-4580            Impact factor:   4.673


  86 in total

1.  Prolyl isomerase Pin1 regulates neuronal differentiation via β-catenin.

Authors:  Kazuhiro Nakamura; Isao Kosugi; Daniel Y Lee; Angela Hafner; David A Sinclair; Akihide Ryo; Kun Ping Lu
Journal:  Mol Cell Biol       Date:  2012-05-29       Impact factor: 4.272

2.  A PIN1 polymorphism that prevents its suppression by AP4 associates with delayed onset of Alzheimer's disease.

Authors:  Suk Ling Ma; Nelson Leung Sang Tang; Cindy Woon Chi Tam; Victor Wing Cheong Lui; Linda Chiu Wa Lam; Helen Fung Kum Chiu; Jane Ann Driver; Lucia Pastorino; Kun Ping Lu
Journal:  Neurobiol Aging       Date:  2010-06-30       Impact factor: 4.673

3.  Proteomic analysis of brain proteins in APP/PS-1 human double mutant knock-in mice with increasing amyloid β-peptide deposition: insights into the effects of in vivo treatment with N-acetylcysteine as a potential therapeutic intervention in mild cognitive impairment and Alzheimer's disease.

Authors:  Renã A S Robinson; Gururaj Joshi; Quanzhen Huang; Rukhsana Sultana; Austin S Baker; Jian Cai; William Pierce; Daret K St Clair; William R Markesbery; D Allan Butterfield
Journal:  Proteomics       Date:  2011-09-22       Impact factor: 3.984

4.  Increased levels of 4-hydroxynonenal and acrolein in the brain in preclinical Alzheimer disease.

Authors:  M A Bradley; W R Markesbery; M A Lovell
Journal:  Free Radic Biol Med       Date:  2010-02-18       Impact factor: 7.376

5.  Involvement of Stat3 in mouse brain development and sexual dimorphism: a proteomics approach.

Authors:  Fabio Di Domenico; Gabriella Casalena; Rukhsana Sultana; Jian Cai; William M Pierce; Marzia Perluigi; Chiara Cini; Alessandra Baracca; Giancarlo Solaini; Giorgio Lenaz; Jia Jia; Suzan Dziennis; Stephanie J Murphy; Nabil J Alkayed; D Allan Butterfield
Journal:  Brain Res       Date:  2010-09-25       Impact factor: 3.252

6.  Acrolein induces selective protein carbonylation in synaptosomes.

Authors:  C F Mello; R Sultana; M Piroddi; J Cai; W M Pierce; J B Klein; D A Butterfield
Journal:  Neuroscience       Date:  2007-06-14       Impact factor: 3.590

Review 7.  Proteomic approaches to quantify cysteine reversible modifications in aging and neurodegenerative diseases.

Authors:  Liqing Gu; Renã A S Robinson
Journal:  Proteomics Clin Appl       Date:  2016-11-11       Impact factor: 3.494

8.  Age-associated oxidative damage to the p62 promoter: implications for Alzheimer disease.

Authors:  Yifeng Du; Michael C Wooten; Marla Gearing; Marie W Wooten
Journal:  Free Radic Biol Med       Date:  2008-11-21       Impact factor: 7.376

Review 9.  A common biological mechanism in cancer and Alzheimer's disease?

Authors:  M I Behrens; C Lendon; C M Roe
Journal:  Curr Alzheimer Res       Date:  2009-06       Impact factor: 3.498

Review 10.  Amyloid β-peptide (1-42)-induced oxidative stress in Alzheimer disease: importance in disease pathogenesis and progression.

Authors:  D Allan Butterfield; Aaron M Swomley; Rukhsana Sultana
Journal:  Antioxid Redox Signal       Date:  2013-02-14       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.